What are the risks of taking Trovan?
FDA issued a Public Health Advisory to inform physicians and the public regarding new safety information about Trovan (trovafloxacin/alatrofloxacin), an antibiotic used to treat many different types of infections. Trovafloxacin was approved for marketing in December, 1997, and became available on the market in February, 1998. Its approved indications include many (14) types of infections that constitute a wide range of degrees of seriousness. Based on new safety data related to serious liver injury, the FDA is advising physicians that trovafloxacin should be reserved for treatment ONLY in patients who meet ALL of the following criteria: 1) Those who have at least one of five types of serious and life or limb-threatening infections listed below that is judged by the treating physician to be serious and life or limb-threatening; • Nosocomial pneumonia (pneumonia acquired in the hospital) • Community acquired pneumonia • Complicated intra-abdominal infections, including post-surgical infe
